Skip to main content

Table 3 Post-diagnostic use of warfarin compared to anticoagulant non-users and seperately to users of other types of anticoagulants stratified by Defined Daily Doses (DDD), duration and intensity of usage

From: Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer

 

n of deaths

Age-adjusted

Multivariable-adjusted

1-year lag-time

2-year lag-time

3-year lag-time

Warfarin compared to non-users

 None

509

Ref

Ref

Ref

Ref

Ref

 Any

121

1.46 (1.12-1.90)

1.47 (1.13-1.93)

1.12 (0.85-1.48)

1.12 (0.85-1.48)

1.08 (0.83-1.41)

Amount of warfarin use

 ≤200 DDD

63

2.47 (1.84-3.31)

2.50 (1.86-3.36)

1.45 (1.04-2.02)

1.34 (0.99-1.83)

1.26 (0.94-1.70)

 200-667 DDD

32

0.87 (0.53-1.42)

0.88 (0.54-1.46)

0.85 (0.52-1.41)

0.76 (0.44-1.32)

0.76 (0.43-1.36)

 >667 DDD

26

0.97 (0.56-1.68)

1.02 (0.59-1.78)

1.05 (0.60-1.83)

1.15 (0.67-1.97)

1.04 (0.58-1.85)

Duration of warfarin use

 ≤1 year

56

2.03 (1.47-2.81)

2.04 (1.47-2.83)

1.26 (0.89-1.78)

1.25 (0.91-1.71)

1.15 (0.85-1.57)

 2-4 years

44

1.28 (0.88-1.87)

1.30 (0.89-1.90)

1.11 (0.73-1.69)

0.87 (0.53-1.42)

0.93 (0.56-1.54)

 5 or more years

21

0.95 (0.49-1.85)

1.05 (0.54-2.04)

1.06 (0.56-1.99)

1.37 (0.76-2.47)

1.22 (0.66-2.26)

Intensity of warfarin use

 ≤128 DDD/year

45

1.92 (1.34-2.74)

1.91 (1.34-2.74)

1.31 (0.91-1.88)

1.35 (0.98-1.86)

1.21 (0.89-1.66)

 128-200 DDD/year

51

1.74 (1.24-2.45)

1.77 (1.25-2.50)

1.13 (0.74-1.74)

0.93 (0.57-1.51)

0.94 (0.57-1.56)

 >200 DDD/year

25

0.73 (0.40-1.33)

0.78 (0.43-1.43)

0.99 (0.58-1.69)

0.97 (0.56-1.69)

0.99 (0.56-1.77)

Warfarin compared to other anticoagulant drugs

 Non-warfarin anticoagulant users

98

Ref

Ref

Ref

Ref

Ref

 Warfarin users

121

1.13 (0.79-1.61)

1.01 (0.71-1.44)

0.93 (0.64-1.35)

1.02 (0.70-1.48)

0.93 (0.65-1.33)

Amount of warfarin use

 ≤200 DDD

63

1.85 (1.25-2.74)

1.63 (1.10-2.42)

1.15 (0.75-1.77)

1.19 (0.78-1.80)

1.06 (0.71-1.58)

 200-667 DDD

32

0.65 (0.37-1.14)

0.58 (0.33-1.01)

0.68 (0.38-1.20)

0.67 (0.36-1.25)

0.64 (0.34-1.21)

 >667 DDD

26

0.72 (0.39-1.33)

0.67 (0.36-1.23)

0.83 (0.45-1.55)

1.02 (0.56-1.87)

0.87 (0.46-1.64)

Duration of warfarin use

 ≤1 year

56

1.52 (1.00-2.31)

1.33 (0.88-2.02)

1.00 (0.64-1.55)

1.11 (0.73-1.68)

0.97 (0.65-1.45)

 2-4 years

44

0.96 (0.61-1.52)

0.85 (0.54-1.34)

0.88 (0.53-1.46)

0.77 (0.44-1.35)

0.78 (0.44-1.38)

 5 or more years

21

0.71 (0.35-1.46)

0.69 (0.34-1.40)

0.84 (0.42-1.67)

1.22 (0.64-2.33)

1.02 (0.53-2.00)

Intensity of warfarin use

 ≤128 DDD/year

45

1.44 (0.93-2.24)

1.25 (0.80-1.95)

1.04 (0.66-1.64)

1.20 (0.78-1.83)

1.02 (0.68-1.53)

 128-200 DDD/year

51

1.31 (0.85-2.01)

1.16 (0.75-1.78)

0.90 (0.54-1.49)

0.82 (0.47-1.44)

0.79 (0.45-1.40)

 >200 DDD/year

25

0.55 (0.29-1.05)

0.51 (0.27-0.98)

0.79 (0.43-1.44)

0.86 (0.46-1.60)

0.83 (0.44-1.57)

  1. Age-adjusted, multivariable-adjusted and lag-time hazard ratios (95% CI) related to all PCa deaths. Statistically significant results are bolded